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Type 2 diabetes is characterized by peripheral insulin
resistance and insufficient insulin release from
pancreatic islet b cells. However, the role and
sequence of b cell dysfunction and mass loss for
reduced insulin levels in type 2 diabetes pathogen-
esis are unclear. Here, we exploit freshly explanted
pancreas specimens frommetabolically phenotyped
surgical patients using an in situ tissue slice technol-
ogy. This approach allows assessment of b cell vol-
ume and function within pancreas samples of meta-
bolically stratified individuals. We show that, in
tissue of pre-diabetic, impaired glucose-tolerant
subjects, b cell volume is unchanged, but function
significantly deteriorates, exhibiting increased basal
release and loss of first-phase insulin secretion. In in-
dividuals with type 2 diabetes, function within the
sustained b cell volume further declines. These re-
sults indicate that dysfunction of persisting b cells
is a key factor in the early development and progres-
sion of type 2 diabetes, representing a major target
for diabetes prevention and therapy.
INTRODUCTION
Type 2 diabetes is a metabolic disorder that causes hyperglyce-
mia in patients and affects hundreds of millions of people world-
wide. It is responsible for debilitating long-term complications,
decreased quality of life, and premature death. Unfortunately,
present treatment options are unable to adequately control hy-
perglycemia and prevent the negative impact of type 2 diabetes.
Development of effective therapeutic approaches to correctThis is an open access article undinadequate insulin levels in response to elevated blood glucose
relies on targeting the correct underlying pathological mecha-
nism. However, it is still under debate whether and at which
stage of diabetes pathogenesis insulin insufficiency is the result
of compromised b cell function (i.e., the amount of insulin
released by each individual b cell), reduced b cell mass (i.e.,
the number of b cells within the pancreas), and/or a combination
of both (Li et al., 2019; Taylor et al., 2019;Weir, 2020). It has been
suggested that b cell mass loss already happens in the early
stage of diabetes before b cell functional impairment (Weir,
2020; Weir and Bonner-Weir, 2004, 2013) and that b cell mass
deficit actually predisposes an organism to impaired glucose ho-
meostasis in diabetes (Costes et al., 2013; Leahy, 2005; Taylor
et al., 2019). On the other hand, by examining the timing and rela-
tionship between changes in blood glucose, b cell volume, and
insulin secretion, arguments have been made that the functional
deficit is more dominant and is requisite for the development of
type 2 diabetes (Ferrannini, 2010; Kahn et al., 2006, 2009; Ritzel
et al., 2006; Saisho, 2014). Hence, it is unclear whether andwhen
the objective in type 2 diabetes prevention and therapy should
be to protect and restore b cell function, i.e., the amount of insu-
lin released by each individual b cell, or to prevent the death of b
cells and increase their mass (Chen et al., 2017; Halban et al.,
2014). A main reason for the inability to address these key ques-
tions is the lack of samples and technologies to simultaneously
assess b cell function andmass. Systemicmetabolic tests in vivo
cannot reliably distinguish between the contribution of number
and function of b cells to plasma insulin levels. At present, b
cell mass in humans can only be assessed by histology of
pancreatic specimens from organ donors or surgical patients,
which do not allow functional testing. Utilizing this approach,
studies have reported a wide range of b cell mass reduction in
subjects with type 2 diabetes, stretching from 24% to 65% (But-
ler et al., 2003; Clark et al., 1988; Inaishi et al., 2016; Rahier et al.,
2008; Sakuraba et al., 2002; Yoon et al., 2003), whereas othersCell Reports 31, 107469, April 7, 2020 ª 2020 The Author(s). 1
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suggested this method to overestimate b cell loss in type 2 dia-
betes (Marselli et al., 2014). In either case, an additional substan-
tial loss of function in the residual b cells seems imperative to
explain the extreme reduction in insulin response found in type
2 diabetes (Ferrannini et al., 2005; Gastaldelli et al., 2004; Hol-
man, 1998; Jensen et al., 2002; Osei et al., 1997; Ward et al.,
1984). Most importantly, current data do not elucidate to which
extent these two distinct components contribute to type 2 dia-
betes pathogenesis and whether loss of b cell mass and/or func-
tion is cause or consequence of the uncontrolled hyperglycemia.
Only limited and conflicting data are available on b cell mass in
pre-diabetes or impaired glucose-tolerant subjects (Butler
et al., 2003; Meier et al., 2009). Consequently, the role of b cell
mass and function in the development of type 2 diabetes and
their importance for prevention and therapy have been contro-
versially discussed (Clark et al., 2001; DeFronzo et al., 2013;
Henquin et al., 2008; Meier and Bonadonna, 2013; Weir and
Bonner-Weir, 2013).
Here, we employed a novel approach of human pancreas tis-
sue slices in combination with a unique collection of fresh
pancreas tissue samples from metabolically phenotyped sub-
jects to simultaneously assess b cell volume and function within
pancreatic tissue. Thereby, we provide direct evidence that
dysfunction of persisting b cells is an early feature of type 2 dia-
betes pathogenesis that remains an important mechanism
throughout disease progression.
RESULTS
Pancreas Tissue Slices of Metabolically Phenotyped
Subjects Allow Assessment of b Cell Volume and
Function in Type 2 Diabetes Pathogenesis
To explore the detailed 3D cellular morphology and insulin secre-
tion of intact human pancreatic tissue under near physiological
conditions, we utilized the pancreas tissue slice technique
(Marciniak et al., 2013, 2014; Speier and Rupnik, 2003) in freshly
explanted surgical samples from subjects who underwent
pancreatectomy (Ehehalt et al., 2015; Sturm et al., 2013). These
subjects, 4 non-diabetic (ND), 4 having impaired glucose toler-
ance (IGT), and 6 type 2 diabetes (Table S1), were part of a larger
cohort of 61ND,71 IGT, and88 type2diabetessubjects (Figure1),
inwhichpatients in thedays immediatelyprior tosurgeryhadbeen
metabolically phenotyped based on their clinical history, HbA1c
(Figure 1A), fasting blood glucose (fBG) levels (Figure 1B), and
an oral glucose tolerance test (OGTT) (Figure 1C) for being either
ND or having IGT or type 2 diabetes, according to the American
Diabetes Association (ADA) guidelines (Solimena et al., 2018).
Within this cohort, the mean age was slightly increased in IGT
and type 2 diabetes subjects in comparison to ND (Figure 1D),
whereas body mass index (BMI) (Figure 1E) and HOMA2-IR (Fig-
ure 1F) did not differ among the three groups. Fasting C-peptide
levels (Figure 1G) were significantly decreased, and fasting proin-
sulin (Figure 1H) significantly increased in type 2 diabetes. As a
result, the insulin/proinsulin ratio was significantly decreased in
IGT and type 2 diabetes in comparison to ND (Figure 1I). Conse-
quently, HOMA2-%B, as an indicator of insulin release, was
significantly different between all groups of the cohort (Figure 1J).
Tissuesamplesobtained immediatelyafter surgeryof thesubjects2 Cell Reports 31, 107469, April 7, 2020providing tissue for this study were further processed by vibra-
tomesectioning toobtain120-mm-thick tissuesliceswithadimen-
sion of ca. 33 3mm (Figure 1K). Only viable tissue slices display-
ing a limited number of dead cells were used for subsequent
assays (Figure S1).
Islet Cell Morphology and Volume Are Not Altered in
Pancreas Tissue Slices of IGT and Type 2 Diabetes
Subjects
Endocrine cell content was quantified by 3Dmorphometry of the
entire slice volume for the three main endocrine cell types at
cellular resolution (Figures 2A–2C). Applying this procedure, we
could quantify the endocrine fraction and cellular distribution
within a given volume of pancreatic tissue (Figure S2). We found
that, in ND subjects, endocrine cells constituted 0.48% ± 0.09%
of pancreas volume (Figure 2D). This was slightly less than the
fractional area previously reported from histological studies (But-
ler et al., 2010; Wang et al., 2013). This difference is probably
related to differences in the experimental and analysis approach
used for the measurement of cell volumes within tissue pieces in
comparison to the assessment of cell area in thin sections.More-
over, tissue used in our study mainly originated from the
pancreas head, which has been reported to contain fewer islets
than the rest of the pancreas (Reers et al., 2009; Saito et al.,
1978). Interestingly, endocrine cell volume was not significantly
changed being 1.06% ± 0.33% and 0.91% ± 0.60% (Figure 2D),
respectively. Similarly, distinct endocrine cell volume fractions of
b, a, and d cells were not significantly altered in pancreas of ND,
IGT, and type 2 diabetes subjects (Figures 2E–2G). In addition,
the mean diameter of all detected endocrine objects, which re-
fers to all hormone-positive-stained cells identified as single cells
(1 cell; volume of 500–1,000 mm3), small clusters (2–10 cells; vol-
ume of 1,001–10,000 mm3), or islets (>10 cells; volume
>10,000 mm3), of up to >250 mm diameter as well as their density
in the pancreatic tissue were comparable between the groups
(Figures 2H and 2I). Furthermore, our analysis demonstrated
that the vast majority of endocrine objects in the human
pancreas, 82.02% ± 3.13%, were individual cells or small clus-
ters of up to 10 endocrine cells scattered throughout the
exocrine tissue (Figures 2J and 2K). However, these single cells
and small clusters only contributed 18.10% ± 4.22% to the over-
all volume of endocrine cells (Figures 2L and 2M). The vast ma-
jority of the endocrine volume was comprised by islets withR11
cells (Figures 2L and 2M). Neither the distribution of endocrine
object size nor their contribution to total endocrine volume was
significantly changed in the pancreas of IGT or type 2 diabetes
subjects (Figures 2H–2M). Thus, detailed 3D morphometry of
endocrine cell volume, composition, and distribution within the
studied human pancreatic tissue revealed no difference between
ND, IGT, and type 2 diabetes subjects.
b Cell Function Is Compromised in Pancreas of IGT
Subjects and Deteriorates in Type 2 Diabetes
Utilizing the unique potential of pancreas tissue slices, we addi-
tionally assessed b cell function by measuring kinetic insulin
secretion. Upon perifusion, pancreas tissue slices from ND sub-
jects showed a typical bi-phasic insulin secretory pattern in
response to elevated glucose levels exhibiting a peak in insulin
Figure 1. Experimental Approach and Clin-
ical Data
(A–C) Parameters used to classify individual pa-
tients prior to surgery into the different disease
groups according to ADA criteria with (A) plasma
HbA1c, (B) plasma fasting blood glucose, and (C)
plasma 2-h blood glucose value during an OGTT.
(D–J) Age (D) and BMI values (E) of patients within
the entire cohort as well as (F) HOMA2-IR, (G)
fasting serum C-peptide, (H) fasting serum proin-
sulin, (I) insulin: proinsulin ratio, and (J) b cell
functional index. (F) and (J) were calculated with
the HOMA2 model calculator (https://www.dtu.ox.
ac.uk/homacalculator/).
(K) Schematic overview of the experimental work-
flow with human patients undergoing partial
pancreatectomy after being metabolically pheno-
typed (A–J). During partial pancreatectomic
surgery, pancreas tissue is resected and non-
cancerous tissue is procured and further pro-
cessed for tissue slice preparation. Viable tissue
slices are subsequently used for fixation and 3D
morphometric analysis or subjected to kinetic in-
sulin secretion.
Gray dots in (A)–(J) represent single patients with
n = 62 (non-diabetic [ND]), n = 71 (impaired glucose
toleranct [IGT]), and n = 88 (type 2 diabetes [T2D]).
Lines show mean ± SEM. Colored dots (ND n = 4;
IGT n = 4; T2D n = 6) represent patients used in the
current study. Statistical analysis was performed
on the entire cohort by one-way ANOVA and post
hoc comparison of disease groups with Sidak’s
correction for multiple comparisons. *p < 0.05.
See also Table S1.secretion during the first phase, followed by a second-phase
plateau (Figures 3A and S3A). Intriguingly, tissue slices from
IGT subjects showed a significantly increased basal insulin
secretion, although glucose-stimulated insulin release was
comparable to ND (Figures 3A–3C and S3A). In contrast, the
baseline insulin secretion of slices from type 2 diabetes pa-
tients was similar to that of slices from ND subjects and signif-
icantly lower compared to IGT (Figures 3A–3C and S3A). More-
over, slices from both IGT and type 2 diabetes subjects lacked
the typical first-phase peak prior to the second-phase plateau
(Figures 3A–3C and S3A). When expressed as stimulation index
to illustrate the stimulatory potential of glucose over baseline,
slices from ND subjects displayed 5-fold increased insulin
secretion during first phase and 3-fold elevated secretion dur-
ing the second phase (Figures 3D and S3B), comparable to
the response observed from islets isolated from ND organ
donors (Figure S4). In contrast, samples from IGT and type 2
diabetes subjects showed a severely diminished stimulation in-
dex leading to a significantly reduced area under the curve of
insulin secretion in first and second phase (Figures 3D–3F
and S3B). Insulin content, in particular when normalized to b
cell volume measured in adjacent slices of the respective pa-
tient (see Figure 2), was strongly reduced in tissue slices ob-tained from type 2 diabetes subjects (Figures 3G and 3H), indi-
cating emptying of insulin granule stores. Consequently, the
insulin secreted from slices of IGT and type 2 diabetes was
increased when expressed as a fraction of their insulin content
(Figures 3I and S3C).
Clinical Parameters of Type 2 Diabetes Pathogenesis
Are Associated with the Functional Decline of b Cells
Furthermore, our approach allowed us to compare b cell function
and volume in pancreas tissue slices directly with various clinical
parameters from the same subjects (Figures 4 and S5). We found
that endocrine cell volume in tissue slices correlated linearly with
age (Figure 4A) of the tissue donors, independent of their status
of glucose homeostasis. However, there was no significant cor-
relation between endocrine cell mass and BMI (Figure 4B),
HbA1c (Figure 4C), or fasting glucose (Figure 4D). Stimulated in-
sulin secretion from tissue slices showed no correlation with age
(Figure 4E) or BMI (Figure 4F) of the donor. Interestingly, when
assessing the relationship of stimulated insulin secretion and
HbA1c (Figure 4G) and fasting glucose (Figure 4H), ND, IGT,
and type 2 diabetes subjects clustered in groups, indicating an
association of b cell function with clinical parameters of type 2
diabetes pathogenesis.Cell Reports 31, 107469, April 7, 2020 3
Figure 2. 3D Histomorphometric Analysis of Human Pancreas Tissue Slices
(A) Maximum intensity projection of an entire human pancreas tissue slice stained with antibodies against insulin (magenta), glucagon (grey), and somatostatin
(yellow) counterstained with DAPI (blue). Scale bar, 500 mm.
(B)Magnifiedmaximum intensity projection of a single islet (boxed in A) with insulin (magenta), glucagon (gray), somatostatin (yellow), and DAPI (blue) in XY (upper
left), XZ (bottom left), and YZ (upper right) orientation. Scale bar, 50 mm.
(C) Maximum intensity projection of the same islet as in (B) for single hormone staining for insulin (magenta), glucagon (gray), and somatostatin (yellow). Scale
bars, 50 mm.
(D–G) Quantification of hormone-positive volumes as percent of the total slice volumes of ND (green), IGT (blue), and T2D (orange) samples for (D) Ins+/Gcg+/Sst+
volume, (E) Ins+ volume, (F) Gcg+ volume, and (G) Sst+ volume.
(H and I) Mean endocrine object diameter (H) and endocrine object density (I) of the individual samples from ND, IGT, and T2D patients.
(J and K) Frequency distribution of hormone-positive endocrine objects by diameter (J) and mean percent of endocrine objects (K) grouped by appearance of
single cells, cluster (up to 10 cells), and islets (>11 cells) for individual samples from ND, IGT, and T2D specimens.
(L and M) Cumulative volume of all endocrine objects by diameter (L) and mean contribution (M) of single cells, cluster (up to 10 cells), and islets (>11 cells) to the
entire endocrine (Ins+/Gcg+/Sst+) volume from individual ND, IGT, and T2D samples. ND n = 4, IGT n = 4, and T2D n = 6 with data presented as mean ± SEM.
See also Figure S2.DISCUSSION
Our data demonstrate that b cells exhibit significant functional
deterioration and exhaustion already at early stages of type 2
diabetes pathogenesis, at which subjects exhibit impaired
glucose tolerance but are not yet diabetic. Conversely, b cell vol-
ume is maintained at this stage of disease progression, which is
in line with the previous finding of unchanged b cell mass in
impaired glucose-tolerant subjects (Meier et al., 2009). Thus,
our results identify b cell dysfunction as an initial feature of dia-
betes development and not necessarily as consequence of a4 Cell Reports 31, 107469, April 7, 2020preceding loss in b cell mass. Interestingly, in non-diabetic sub-
jects with more elevated levels of fasting blood glucose
(>110 mg/dL) b cell mass was reported to be decreased (Butler
et al., 2003). This suggests that non-diabetic individuals with
significantly elevated fasting blood glucose might experience
advanced disease progression or a different etiology of diabetes
pathogenesis in comparison to individuals in pre-diabetic sub-
jects with impaired glucose tolerance (Rizza, 2010). Our study
shows that functional decline of b cells emerges in pancreatic tis-
sue of IGT individuals and manifests as increased basal insulin
release, a known feature of impaired glucose homeostasis
Figure 3. Assessment of b Cell Function In
Situ
(A) Insulin secretion of slices from ND (green), IGT
(blue), and T2D (orange) subjects presented as
absolute secretion in ng/min. G1, KRBH buffer
containing 1 mM glucose; G3, KRBH buffer con-
taining 3mMglucose; G16.7mM, KRBHbuffer with
16.7 mM glucose; KCl, KRBH buffer with 16.7 mM
glucose and 60 mM KCl (final concentration [f.c.]).
(B and C) Area under the curve (AUC) measure-
ments of data in (A) for (B) basal secretion (minutes
0–10) and (C) entire stimulation period (minutes 10–
50) of the individual samples.
(D) Insulin secretory pattern of ND (green), IGT
(blue), and T2D (orange) pancreas tissue slices
during perifusion expressed as fold increase to
basal secretion within the first 10 min (3 mM
glucose).
(E and F) AUC measurements of data presented in
(D) for (E) first-phase insulin secretion (minutes 10–
22) and (F) second-phase insulin secretion (mi-
nutes 28–48) of single samples.
(G) Slice insulin content after perifusion of ND, IGT,
and T2D specimens.
(H) Slice insulin content normalized to Ins+ volume
assessed in adjacent slices for the respective
subject (see also Figure 2).
(I) Insulin secretory pattern of ND (green), IGT
(blue), and T2D (orange) pancreas tissue slices
during perifusion expressed as % of total content.
ND n = 4, IGT n = 4, and T2D n = 6 with data pre-
sented as mean ± SEM.
All data in this figure are analyzed using one-way
ANOVA with post hoc comparison of disease
groups using Sidak’s correction for multiple com-
parisons. *p < 0.05.
See also Figures S3 and S4.observed in individuals with IGT and with predictive value for
type 2 diabetes development (Charles et al., 1991). Yet we
show here that elevated basal insulin secretion appears without
a significant increase in peripheral insulin resistance and occurs
ex vivo in the absence of a direct systemic influence (Weyer et al.,
2000). Additionally, b cells from IGT subjects exhibited a loss of
first-phase insulin release, confirming the early manifestation of
this feature of dysregulated insulin release, previously observed
in IGT subjects in vivo in response to an OGTT (Gerich, 1997).
Similar to elevated basal insulin release, our data demonstrated
that also the loss of first-phase insulin secretion from pancreatic
tissue was the result of b cell dysfunction of an unchanged b cell
volume. Thus, although insulin dysregulation has been shown to
occur in early stages of type 2 diabetes development (Abdul-
Ghani et al., 2006; DeFronzo et al., 2013; Ferrannini et al.,
2005), our study provides further insight into underlying mecha-
nisms by demonstrating an intrinsic b cell defect without concur-
rent changes in b cell mass and independent of systemic insulin
resistance. Notably, recent transcriptomic analysis of pancreatic
surgical samples from subjects within this and a similar cohort
detected no significant transcriptomic changes in laser-capture
microdissected islets of individuals with IGT but only in those
from patients with overt type 2 diabetes (Gerst et al., 2018; Sol-
imena et al., 2018). This indicates that early b cell dysfunction inIGT subjects is not the consequence of alterations in gene
expression but most likely in the levels of other factors, such
as proteins, lipids, carbohydrates, or metabolites. In subjects
with type 2 diabetes, the first phase of insulin release remained
absent, indicating ongoing b cell dysfunction. Moreover, the
basal and second phase of insulin release from pancreas tissue
slices declined in individuals with type 2 diabetes in comparison
to IGT, potentially as a result of long-lasting b cell stress, pro-
gressing b cell dysfunction, and b cell exhaustion. Intriguingly,
in our study, pancreatic tissue obtained from type 2 diabetes
subjects showed no decrease in b cell volume. This is in contrast
to findings of several histological studies on the pancreas from
type 2 diabetes organ donors (Butler et al., 2003; Clark et al.,
1988; Inaishi et al., 2016; Rahier et al., 2008; Sakuraba et al.,
2002; Yoon et al., 2003). Discrepancies concerning b cell mass
among studies can be related to variables like tissue sampling,
processing and analysis, or donor and disease characteristics,
including BMI, age, insulin resistance, glucose tolerance, and
fasting blood glucose levels. In addition, in some studies, b cell
mass might have been underestimated due to the presence of
degranulated and therefore insulin-negative b cells (Marselli
et al., 2014). Although the staining and imaging protocols used
in our study limit the risk of underestimation of b cell mass, we
cannot exclude escaping of a limited number of fullyCell Reports 31, 107469, April 7, 2020 5
Figure 4. Association of Clinical Parameters with b Cell Function and Mass
(A–D) Regression analysis of endocrine cell volume (see Figure 2D) to (A) age, (B) BMI, (C) HbA1c, and (D) fasting blood glucose.
(E–H) Regression analysis of AUC values from insulin secretion (stimulation index) during stimulating conditions with 16.7 mM glucose (see Figure 3B) to (E) age,
(F) BMI, (G) HbA1c, and (H) fasting blood glucose. ND (green) n = 4; IGT (blue) n = 4; T2D (orange) n = 6.
See also Figure S5.degranulated b cells. However, a potential underestimation of b
cell mass in IGT and type 2 diabetes would further strengthen our
observation that b cell function and not mass is declined in slices
of these patient groups. Given the strong overlap of reported b
cell mass ranges in type 2 diabetes and non-diabetic individuals
(Rahier et al., 2008), additional studies will be necessary to verify
the sustained b cell volume found in the here studied cohort and
samples. Nevertheless, our results clearly demonstrate that,
even at full-blown type 2 diabetes, there are significant numbers
of dysfunctional b cells present, which potentially can be func-
tionally recovered by appropriate therapies, e.g., via the removal
of potential systemic causes for b cell dysfunction and allowing
restoration of secretory capacity.
When assessing the impact of our study and its relevance for
the understanding of type 2 diabetes pathogenesis, specific
considerations have to be made. First, due to the complexity
of the protocol, we could only obtain and investigate fresh and
viable pancreas tissue slices from a limited number of surgical
donors. Thus, given the observed heterogeneity of pancreas
and diabetes pathogenesis in humans, studies with larger popu-
lations will be necessary to confirm the general applicability of
our findings. Nevertheless, the here applied direct correlation
of detailed systemic metabolic parameters with organ cell
morphology and function in the same individual facilitated the
detection of pathogenic phenotypes as never possible before.
In doing so, our data provide further insight into a controversially
discussed aspect of type 2 diabetes pathogenesis. Second,
subjects in our cohort underwent pancreatectomy mostly due6 Cell Reports 31, 107469, April 7, 2020to a localized tumor. An effect of the neighboring tumor on the
here-studied healthy tissue cannot be fully excluded, albeit pa-
thology examination did neither reveal infiltration of cancer cells
in the islets nor signs of insulitis. Moreover, a previous study on
samples from this cohort did not detect any effect of the present
tumor on islet cell gene transcription in the healthy tissue (Soli-
mena et al., 2018). Furthermore, no relationship between
different cancer types and islet biology was observed in this or
the previous study. Most importantly, in the vast majority of
cases in which diabetes is associated with pancreatic cancer,
diabetes has been shown to manifest concomitantly or less
than 2 years prior to cancer diagnosis (Gullo et al., 1994; Pannala
et al., 2008). In contrast, subjects included in our study had either
no or long-standing diabetes (3, 6, 10, 15, 17, and 20 years dura-
tion), implicating no connection between the state of glucose ho-
meostasis and the cancer. To avoid assessing tumor-related b
cell changes, subjects with recent onset diabetes were not
included in our study. Therefore, we are confident that our results
reflect physiological and pathophysiological processes underly-
ing type 2 diabetes development. Third, in our study, the
pancreas tissue samples were mostly derived from the head of
the pancreas. Our conclusions on the performance of each
pancreas are therefore limited to this respective area and cannot
exclude different developments in a different part of the
pancreas. This could be relevant, as islet composition and den-
sity differ between the posterior part of the head and the tail of
the pancreas (Gersell et al., 1979; Saito et al., 1978). Interest-
ingly, islets in the pancreas head have been suggested to be
preferentially affected inmetabolically challenging and patholog-
ical conditions (Ellenbroek et al., 2017; Savari et al., 2013; Wang
et al., 2013). However, these considerations do not affect our
conclusion of b cell dysfunction, manifesting as increased basal
and loss of stimulated first-phase insulin secretion in persisting b
cells, being an early crucial feature in the development of type 2
diabetes. Whether this is primarily occurring in islets in the
head of the pancreas or also in the body and tail will need to
be addressed in future studies. Finally, our cohort mainly
consists of type 2 diabetes patients of relatively older age and
with only moderate metabolic derangements, having no signifi-
cant changes in fasting insulin levels or HOMA2-IR compared
to ND subjects. Based on these clinical characteristics, our
findings may not be directly transferable to all type 2 diabetes
patients without additional studies. However, a recent study
on almost 9,000 patients, which led to stratification of adult-
onset diabetes patients into five different subgroups, showed
that patients exhibiting rather modest metabolic alterations
(defined as MARD for mild-age-related diabetes), similar to the
subjects in our cohort, represent the largest patient group of
adult-onset diabetes (Ahlqvist et al., 2018), further stressing
the importance of our findings. Within future studies, it will be
interesting to investigate whether our here-described mecha-
nism of type 2 diabetes pathogenesis also applies to the
pancreas of type 2 diabetes subgroups with different metabolic
characteristics.
In conclusion, using the combination of an in situ tissue tech-
nology and acute human pancreas specimens of metabolically
phenotyped subjects, we demonstrate that deteriorated function
of b cells plays a crucial role at initial stages of type 2 diabetes
development and persists throughout disease progression. We
show that dysregulated insulin release, in the form of increased
basal and loss of first-phase secretion, manifests at a pre-dia-
betic IGT state as result of b cell dysfunction within a sustained
b cell volume. Thus, our results provide experimental evidence
for a unique and unparalleled depiction of the pathogenesis of
human type 2 diabetes, highlighting b cell dysfunction as a crit-
ical target for the development of successful diabetes prevention
and therapy.STAR+METHODS
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Antibodies
Guinea-pig polyclonal anti insulin Dako Cat# A-0546; RRID:AB_10013624
Mouse monoclonal anti glucagon Sigma Cat# G2654; RRID:AB_259852
Rat polyclonal anti somatostatin Abcam Cat# ab30788; RRID:AB_778010
Goat anti-guinea-pig Secondary Antibody Alexa Fluor 488 Thermo Fisher Scientific Cat# A-11073; RRID:AB_2534117
Goat anti-rat Secondary Antibody Alexa Fluor 546 Thermo Fisher Scientific Cat# A-11081; RRID:AB_141738
Goat anti-mouse Secondary Antibody Alexa Fluor 633 Thermo Fisher Scientific Cat# A-21050; RRID:AB_141431
Biological Samples
Human tissue University Clinic Carl Gustav Carus,
Dresden
N/A
Chemicals, Peptides, and Recombinant Proteins
Aprotinin Sigma Cat# A6106
DAPI Sigma Aldrich Cat# D9542
Fluorescein diacetate Sigma Cat# F7378
Low melting point agarose Carl Roth Cat# 6351.1
Propidium iodide Life Technologies Cat# P1304MP
Critical Commercial Assays
Insulin Ultra Sensitive Assay HTRF Kit Cisbio Cat# 62IN2PEH
Software and Algorithms
GraphPad PRISM 6.01 GraphPad Software, La Jolla,
California, USA
http://www.graphpad.com
Fiji Schindelin et al., 2012 https://fiji.sc/
MorphoLibJ Legland et al., 2016 https://imagej.net/MorphoLibJ
Other
Perifusion System Biorep Technologies, USA Cat# PERI4-02-230-FA
Semiautomatec vibratome VT1200S Leica Cat# 14048142066
LSM780 NLO Confocal microscope Zeiss N/A
Closed perifusion chamber + platform Warner Instruments Cat# 64-0223 and 64-0281LEAD CONTACT AND MATERIALS AVAILABILITY
This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to
and will be fulfilled by the Lead Contact, Stephan Speier (stephan.speier@tu-dresden.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The here presented study was approved by the local ethics committee (‘‘Ethik-Kommission der Medizinischen Fakultät Carl Gustav
Carus der Technischen Universität Dresden’’). Written informed consent was received from all participants prior to inclusion in the
study. Human pancreatic tissue was obtained through a collaboration between the Paul Langerhans Institute Dresden and the Uni-
versity Clinic Carl Gustav Carus which was initiated as part of the IMI IMIDIA consortium (Solimena et al., 2018) and continued in the
IMI RHAPSODY and INNODIA consortia. Patients undergoing partial pancreatectomy were thoroughly metabolically phenotyped
prior to surgery and classified into groups of non-diabetic (ND, n = 4), impaired glucose tolerant (IGT, n = 4) and type 2 diabetic
(T2D, n = 6). Age/sex and metabolic parameters were provided for all patients (Table S1)e1 Cell Reports 31, 107469, April 7, 2020
METHOD DETAILS
Tissue Procurement, Processing and Slicing
Within 1.5 hours after explant, surgical tissue specimens were placed into ECS solution (125mM NaCl, 2.5mM KCl, 26mM NaHCO3,
1.25mM NaH2PO4, 1mM MgCl2, 2mM CaCl2, 10mM HEPES, 3mM glucose, pH 7.4) and processed into smaller tissue blocks by
removing connective, adipose and fibrotic tissue. Up to four small tissue pieces of ca. 3x3x3mm were placed into a 3,5cm Petri
dish and covered with 3,8% lowmelting point agarose (Carl Roth, 6351.1) preheated to 37C. Once agarose was solidified, the small
agarose cubes containing tissue blocks were mounted using tissue glue (Superglue 90-120 CPS, World Precision Instruments, Inc,
cat. no. 7341) on the specimen holder of a semiautomatic vibratome (Leica VT1200S, cat. no. 14048142066) and the buffer tray was
filled with cold ECS solution. Slicing was performed at a step size of 120 mm, speed of 0.1mm/s, amplitude of 1mm and an angle of
15. Slices were collected into a 6cmPetri dish containing 3mMglucose KRBHbuffer (137mMNaCl, 5.36mMKCl, 0.34mMNa2HPO4,
0.81mM MgSO4, 4.17mM NaHCO3, 1.26mM CaCl2, 0.44mM KH2PO4, 10mM HEPES, 0.1% BSA, 3mM glucose, pH 7.3) with apro-
tinin (25KIU/mL, Sigma, cat. no. A6106) and kept for 60 minutes at room temperature while shaking, before performing any further
experiments.
Tissue Viability
Tissue viability was assessed after slicing using FDA/PI staining. Two slices of each embedded block were incubated with propidium
iodide staining solution (f. c. 0.1mg/mL in PBS, Life technologies, cat. no. P1304MP-100mg) for 1-2 minutes at room temperature
while shaking. Fluorescein diacetate (f.c. 0.05mg/mL in PBS, Sigma, cat. no. F7378-5g) was added to the staining solution and incu-
bated for 2 minutes at room temperature in the dark, while shaking. Slices were transferred into PBS (Sigma, cat. no. D8537-500ml)
and imaged using a confocal microscope (LSM 780 NLO, Zeiss). If propidium iodide positive cells within the tissue (excluding the
cutting surface) exceeded 10%, we excluded the patient from the study.
Perifusion
Four slices originating from different embedded blocks were placed into a closed perifusion chamber (Warner Instruments, cat. no.
64-0223 and cat. no. 64-0281 (P-5)) and connected to a perifusion system with automated tray handling (Biorep Technologies, cat.
no. PERI4-02-230-FA). In order to equilibrate the slices to 37C and to wash out accumulated hormones and enzymes from the tis-
sue, a 60-minute flushing step with 3mM KRBH at a flow rate of 100 mL/min was performed. Subsequently, the actual perifusion pro-
tocol was applied using a flow rate of 100mL/min and samples were collected in 96-well plates containing aprotinin at a final concen-
tration of 25 KIU/mL at an interval of 2 minutes. After the perifusion experiments, tissue slices were lysed for total insulin content
measurements using 500 mL acid ethanol (2% HCl [37%, 12M] in abs. ethanol). Samples were kept at 20C until measured with
an Insulin Ultra Sensitive Assay Kit (Cisbio, cat. no. 62IN2PEH).
Immunofluorescent staining
Slices were fixed with 4% paraformaldehyde for 30 minutes at room temperature and kept in PBS at 4C until staining. All antibody
solutions were prepared in staining buffer containing 30% goat serum, 900mM NaCl, 40mM sodium phosphate buffer (pH 7.4) and
0.6%Triton X-100. Slices were incubatedwith primary antibodies against insulin (1:500, guinea-pig, Dako, cat. no. A-0546), glucagon
(1:2000,mouse, Sigma, cat. no. G2654) and somatostatin (1:200, rat, Abcam, cat. no. ab30788) overnight at 4Cwhile shaking. Slices
were washed three times for at least 30 minutes with PBS and incubated with secondary antibodies: AlexaFluor 488 goat anti-
guinea-pig (1:200, Invitrogen, cat. no. A-11073), AlexaFluor 633 goat anti-mouse (1:200, Invitrogen, cat. no. A-21050) AlexaFluor
546 goat anti-rat (1:200, Invitrogen, cat. no. A-11081) and DAPI (2.5mg/ml, Sigma Aldrich, cat. no. D9542) overnight at 4C while
shaking. Slices were washed three times for at least 30 minutes with PBS and kept at 4C in the dark until imaging.
Imaging and Analysis
Single islet images were obtained using an upright laser scanning confocal microscope (LSM 780 NLO, Zeiss) with a Plan-Apochro-
mat 20x/1$0 water-immersion objective (Zeiss) using a stack separation of 1.5 mm. For the assessment of 2D islet morphology, 10-20
islets per patient were imaged from at least 3 different slices and analysis was performed manually on three z-planes per islet at a
distance of 15 mmusing Fiji (Schindelin et al., 2012). Islet cell composition was expressed as the average of the three planes analyzed.
For imaging of entire tissue slices, tile-scans were performed with 2-4 stained slices per patient mounted under a poly-L-lysine
coated 22x22mm glass coverslip submerged in PBS (pH 7.4) using an upright laser scanning confocal microscope (LSM 780
NLO, Zeiss), with a Plan-Apochromat 20x/1.0 water-immersion objective (Zeiss) and an automated stage (Zeiss). Single tiles were
imaged at a resolution of 0.75x0.75mm, a tile overlap of 15%, and stack separation of 2.5mm. The bounding grid was set around
the slice such that the entire slice was included in the tile-scan, and the stack boundaries were set to include the entire slice.
Tile-Scan Analysis
Raw tile-scans were stitched using the Fiji Stitching plugin (Preibisch et al., 2009; Schindelin et al., 2012). Fusion was completed by
maximum intensity, with a regression threshold of 0.3, maximum displacement threshold of 2.50, and absolute displacement
threshold of 3.50. The overlap was computed with sub pixel accuracy. Stitched tile-scans were contoured manually for the total sliceCell Reports 31, 107469, April 7, 2020 e2
area and for all individual endocrine objects (defined as positive for at least one hormone stained) on a maximum intensity projection,
with the ROIs saved separately. For individual endocrine objects, the regions were individually cropped from the stitched tile-scan,
the 488 channel was subtracted from the 546 channel, and the 546 channel was subtracted from the 633 channel to account for chan-
nel bleed. The images were then split by color, median filtered (3x3x1), and each converted to binary (IJ_IsoData). Hole filling in 3D
and size opening (limit 500 mm3), followed by volume analysis (Euler connectivity: C26) were completed using MorphoLibJ (Legland
et al., 2016). For total slice volume, each channel of the original tile-scan was added together, and then cropped using the total slice
ROI previously contoured. The image was median filtered (3x3x1), and a mask of nearby points was generated (within a distance of
10.0mm, threshold of 12.75) using the built in Fiji plugin. Dark and bright outliers (respectively) with a radius of 20 pixels each were
removed. Holes were filled, 3D volume closing was run (cube, 3x3x1), and volume analysis was completed as for the endocrine ob-
jects using MorphoLibJ (Legland et al., 2016). Analyzed volumes and endocrine object counts were pooled by patient number for the
purposes of statistical analysis. For further analysis, endocrine objects were grouped by volume into single cells (500 – 1,000mm3),
small endocrine clusters (1,001 – 10,000mm3, corresponding volume for 2-10 cells) and islets (> 10,000mm3, corresponding volume of
11 or more cells). Comparing endocrine cell composition of similar sized islets assessed by volumetric 3D morphometry of entire tis-
sue slices and manual 2D analysis of single image sections of an islet, we verified that semi-automated large-scale 3D morphometry
delivers the same precision as conventional manual cell counting in 2D, while providing a much larger amount of data with more spe-
cific and relevant information about pancreas morphology (Figure S6).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analyses and Calculations
No specific statistical methods were used to predetermine sample size. All results are presented asmean ± SEM. The significance of
the difference between groups was analyzed as described in the figure legends. P values < 0.05 were considered statistically signif-
icant. All statistical analyses were performed using GraphPad Prism Software version 6.01.
DATA AND CODE AVAILABILITY
This study did not generate any unique datasets or codee3 Cell Reports 31, 107469, April 7, 2020
